Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)

Ip, Kendice; Carvalho, Maria; Shan, Ashley; Banov, Daniel

Abstract

Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)

Author(s): Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel

Issue: Jul/Aug 2017 - Volume 21, Number 4

View All Articles in Issue

Page(s): 322-329

Download in electronic PDF format for $75

Abstract

Budesonide is a corticosteroid that has been shown effective in the treatment of eosinophilic esophagitis, but there are currently no commercial medicines to treat this chronic allergic/immune condition, despite its prevalence in the U.S. Therefore, pharmaceutical compounding is the alternative choice to meet the therapeutic need of eosinophilic esophagitis patients. Two budesonide mucoadhesive oral suspensions (1 mg/10 mL and 2 mg/10 mL) were developed using the compounding vehicle MucoLox, a proprietary mucoadhesive polymer blend that promotes mucosal adhesion. The physical and chemical stability of the oral suspensions was tested over a period of 182 days, at room temperature and refrigerated conditions, in order to determine the corresponding beyond-use date. The physical characterization consisted in observing all samples for color/appearance and odor, and testing for pH and density, whereas the chemical characterization consisted in ultra-performance liquid chromatography assay testing. Both oral suspensions were proven physically and chemically stable, and the ultra-performance liquid chromatography method was proven stability indicating. As a result, the beyond-use date of the budesonide 1-mg/10-mL and 2-mg/10-mL mucoadhesive oral suspensions (MucoLox), in amber plastic bottles, is six months at both room temperature and refrigerated conditions.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2017 Pg. 322-329	Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Author(s): Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
Jul/Aug 2012 Pg. 288-293	Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide Author(s): Zur Eyal
Jul/Aug 2018 Pg. 317	Budesonide 1-mg//10-mL Mucolox Oral Suspensions Author(s): Allen Loyd V Jr
Jul/Aug 2021 Pg. 323	Budesonide 0.0.25% Mucoadhesive Gel Author(s): Allen Loyd V Jr
Mar/Apr 2004 Pg. 101-105	Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs Author(s): Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
Jul/Aug 2001 Pg. 310-312	Wetting and/or Solubilizing Agents, Featured Excipient: Author(s): Allen Loyd V Jr
May/Jun 2013 Pg. 254-261	Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline Author(s): Klemmer Anja, Krämer Irene, Kamin Wolfgang
Mar/Apr 2016 Pg. 155-158	Utilization of Compounded Medications in an Oral Medicine Practice Author(s): Stock Shannon, Rubino Katie, Woo Sook-Bon, Margolis Arthur, Thomas Irena, Aboalela Ali, Treister Nathaniel
Jan/Feb 2018 Pg. 66-75	Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension Author(s): Manchanda Arushi, Laracy Melissa, Savji Taslim, Bogner Robin H
Jan/Feb 2023 Pg. 72-77	Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base Author(s): Spennacchio Antonio, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
Sep/Oct 2010 Pg. 430-435	Quality Control and Physical and Chemical Stability of Hydrocortisone Oral Suspension: An Interlaboratory Study Author(s): Santoveña A, Llabrés M, Fariña JB
Nov/Dec 1999 Pg. 496-500	Enhancement of Skin Penetration of Nonsteroidal Anti-Inflammatory Drugs from Extemporaneously Compounded Topical-Gel Formulations Author(s): Goodwin Donald A, Fuhram L Clifton
Nov/Dec 2023 Pg. 490	Curcumin 1% Intranasal Mucoadhesive Gel Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 431-439	Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt Author(s): Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
Jan/Feb 2018 Pg. 60-65	Effects of Compounded Stanford Modified Oral Rinse (MucoLox) on the Survival and Migration of Oral Keratinocytes and Fibroblasts: Implications for Wound Healing Author(s): Song Guiyun, Banov Daniel, Bassani August S
Jul/Aug 2020 Pg. 327-336	Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Sep/Oct 2021 Pg. 416	Dexamethasone 1-mg/mL in Oral Mix or Oral Mix SF Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2016 Pg. 167-174	Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions Author(s): Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MA
May/Jun 2018 Pg. 240-246	Investigation of the Physical, Chemical, and Microbiological Stability of Oral Solutions Compounded with Herbals Author(s): Khokhlova Kateryna O, Zdoryk Oleksandr A
Mar/Apr 2017 Pg. 160-163	Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions Author(s): Kabiche Djamila, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel